• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis

May 1, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
native infant
5
SHARES
11
VIEWS
Share on FacebookShare on Twitter


native infant
Credit: Pixabay/CC0 Public Domain

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The Lancet Child & Adolescent Health journal.

RSV is a leading cause of serious respiratory illness in young children, particularly in the first six months of life, and is responsible for millions of hospitalizations of children around the world every year.

After successful clinical trials, nirsevimab was approved by several regulatory agencies in 2023 and national programs to provide infants with the monoclonal antibody injection have since been implemented in several high-income countries. This study confirms that the reduction in rates of severe RSV infections observed in clinical trials of nirsevimab can also be achieved in national rollouts of the antibody injection.

It’s important to note that nirsevimab is not a vaccine despite being delivered as an injection. Monoclonal antibodies are proteins developed in a laboratory that mimic the immune system’s ability to fight off harmful viruses, whereas vaccines prompt the body’s immune system to produce an immune response itself.

The meta-analysis of 27 studies conducted during the 2023–2024 RSV season across five countries (France, Italy, Luxembourg, Spain, United States) found on average that nirsevimab reduces the risk of hospitalization due to RSV infection by 83%, intensive care admissions by 81%, and instances of lower respiratory tract infections by 75% in children aged 12 months and younger.

Nirsevimab was associated with higher effectiveness in preventing RSV-related hospitalization in infants older than 3 months (81%) compared to those aged 3 months or younger (76%).

The analysis also found the effectiveness of nirsevimab for RSV-related hospitalization varied by country, with higher effectiveness in the US (93%) than in Spain (83%) and France (76%).

Authors suggest this may be due to a higher proportion of infants at high risk of severe disease receiving nirsevimab in the US, as these infants were prioritized during the 2023-2024 RSV season due to a limited supply of nirsevimab in the US. However, this theory requires further investigation.

The authors say their findings support the use of nirsevimab as a critical intervention for preventing RSV disease and severe outcomes among infants. However, they caution that the included studies were observational, which may introduce bias due to potential factors such as underlying health conditions, socioeconomic status, or regional differences in health care access.

More information:
Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis, The Lancet Child & Adolescent Health (2025). DOI: 10.1016/S2352-4642(25)00093-8

Citation:
Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis (2025, May 1)
retrieved 1 May 2025
from https://medicalxpress.com/news/2025-05-monoclonal-antibody-strong-real-world.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



native infant
Credit: Pixabay/CC0 Public Domain

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The Lancet Child & Adolescent Health journal.

RSV is a leading cause of serious respiratory illness in young children, particularly in the first six months of life, and is responsible for millions of hospitalizations of children around the world every year.

After successful clinical trials, nirsevimab was approved by several regulatory agencies in 2023 and national programs to provide infants with the monoclonal antibody injection have since been implemented in several high-income countries. This study confirms that the reduction in rates of severe RSV infections observed in clinical trials of nirsevimab can also be achieved in national rollouts of the antibody injection.

It’s important to note that nirsevimab is not a vaccine despite being delivered as an injection. Monoclonal antibodies are proteins developed in a laboratory that mimic the immune system’s ability to fight off harmful viruses, whereas vaccines prompt the body’s immune system to produce an immune response itself.

The meta-analysis of 27 studies conducted during the 2023–2024 RSV season across five countries (France, Italy, Luxembourg, Spain, United States) found on average that nirsevimab reduces the risk of hospitalization due to RSV infection by 83%, intensive care admissions by 81%, and instances of lower respiratory tract infections by 75% in children aged 12 months and younger.

Nirsevimab was associated with higher effectiveness in preventing RSV-related hospitalization in infants older than 3 months (81%) compared to those aged 3 months or younger (76%).

The analysis also found the effectiveness of nirsevimab for RSV-related hospitalization varied by country, with higher effectiveness in the US (93%) than in Spain (83%) and France (76%).

Authors suggest this may be due to a higher proportion of infants at high risk of severe disease receiving nirsevimab in the US, as these infants were prioritized during the 2023-2024 RSV season due to a limited supply of nirsevimab in the US. However, this theory requires further investigation.

The authors say their findings support the use of nirsevimab as a critical intervention for preventing RSV disease and severe outcomes among infants. However, they caution that the included studies were observational, which may introduce bias due to potential factors such as underlying health conditions, socioeconomic status, or regional differences in health care access.

More information:
Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis, The Lancet Child & Adolescent Health (2025). DOI: 10.1016/S2352-4642(25)00093-8

Citation:
Monoclonal antibody provides strong real-world protection against severe RSV in infants, suggests meta-analysis (2025, May 1)
retrieved 1 May 2025
from https://medicalxpress.com/news/2025-05-monoclonal-antibody-strong-real-world.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Millions of dimes spill onto Texas highway after truck rolls

Next Post

World’s biggest solar scope sees sunspots as never before

Related Posts

World Health Assembly extends Global Strategy on Digital Health to 2027

World Health Assembly extends Global Strategy on Digital Health to 2027

May 24, 2025
4
genetics

Experts urge tighter sperm donation rules after cancer-linked gene passed to children

May 23, 2025
5
Next Post
World’s biggest solar scope sees sunspots as never before

World’s biggest solar scope sees sunspots as never before

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Diagram showing how a candle is imprinted upside-down on the back of our eyes

Do Eyes Really See The World Upside Down? Here’s The Science. : ScienceAlert todayheadline

May 24, 2025

SpaceX blames Starship Flight 8 mishap on engine hardware failure

May 24, 2025
Forensic police investigate on the railway platform

17 hurt in knife attack at German train station; woman arrested

May 24, 2025
The Straits Times logo

Australia begins clean-up after floods kill 5, damage 10,000 properties

May 24, 2025

Recent News

Diagram showing how a candle is imprinted upside-down on the back of our eyes

Do Eyes Really See The World Upside Down? Here’s The Science. : ScienceAlert todayheadline

May 24, 2025
3

SpaceX blames Starship Flight 8 mishap on engine hardware failure

May 24, 2025
2
Forensic police investigate on the railway platform

17 hurt in knife attack at German train station; woman arrested

May 24, 2025
3
The Straits Times logo

Australia begins clean-up after floods kill 5, damage 10,000 properties

May 24, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Diagram showing how a candle is imprinted upside-down on the back of our eyes

Do Eyes Really See The World Upside Down? Here’s The Science. : ScienceAlert todayheadline

May 24, 2025

SpaceX blames Starship Flight 8 mishap on engine hardware failure

May 24, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co